Chelsea Therapeutics' CEO Discusses Completion Of EoR Meeting With FDA For Northera Capsules NDA (Transcript)

Chelsea Therapeutics International, Ltd. (CHTP)

Completion of EoR Meeting with FDA for Northera Capsules NDA

May 23, 2012 8:30 AM ET

Executives

Kathryn McNeil – Head-Investor & Media Relations

Simon Pedder – President & CEO

Nick Riehle – VP-Administration and CFO

Bill Schwieterman – Chief Medical Officer

Art Hewitt – Chief Scientific Officer

Analysts

Robyn Karnauskas – Deutsche Bank Securities, Inc.

Alan Carr – Needham & Company

Liana Moussatos – Wedbush Securities, Inc.

Juan Sanchez – Ladenburg Thalmann Securities.

Steven Salamon – ROSALIND Advisors

Presentation



Operator

Compare to:
Previous Statements by CHTP
» Chelsea Therapeutics' CEO Hosts Conference to Discuss FDA's CRL to Northera (Transcript)
» Chelsea Therapeutics International's CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Chelsea Therapeutics' CEO Presents FDA Advisory Committee Update - Conference Call (Transcript)
» Chelsea Therapeutics International's CEO Discusses Q3 2011 Results - Earnings Call Transcript

Good day ladies and gentlemen, and welcome to the Chelsea Therapeutics May 22 Conference Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions)

As a reminder this conference is being recorded.

I would now like to turn the call over to your host, Kathryn McNeil. Please go ahead.

Kathryn McNeil

Thank you operator. Good morning everyone and thank you for joining us for our call this morning. A press release related to today’s call can be found on our website, www.chelseatherapeutics.com.

Joining me from Chelsea this morning is Simon Pedder, our President, Chief Executive Officer, Mr. Nick Riehle, our Chief Financial Officer, Dr. Bill Schwieterman, Chief Medical Officer and Dr. Art Hewitt, Chief Scientific Officer.

Following formal remarks by Dr. Pedder, the conference call will open for questions. However, before I turn the call over to Dr. Pedder to get us going, let me note that some of the remarks you’ll hear today contain forward-looking statements regarding future events including our intention to modify the primary endpoint for Study 306B, submit additional data to the FDA, resubmit the NDA for the treatment of Neurogenic OH, anticipated expenses for 2012, cash levels and liquidity to fund the company’s operating plans and the company’s anticipated performance.

1 2 3 Next › Last »